Cargando…
Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern
Evaluating long-term protection against SARS-CoV-2 variants of concern in convalescing individuals is of high clinical relevance. In this prospective study of a cohort of 46 SARS-CoV-2 patients infected with the Wuhan strain of SARS-CoV-2 we longitudinally analyzed changes in humoral and cellular im...
Autores principales: | Odak, Ivan, Schultze-Florey, Christian R., Hammerschmidt, Swantje I., Ritter, Christiane, Willenzon, Stefanie, Friedrichsen, Michaela, Ravens, Inga, Sikora, Ruth, Bayir, Lâle M., Gutierrez Jauregui, Rodrigo, Bernhardt, Günter, Stankov, Metodi V., Cossmann, Anne, Hansen, Guido, Krey, Thomas, Cornberg, Markus, Koenecke, Christian, Behrens, Georg M. N., Bošnjak, Berislav, Förster, Reinhold |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964088/ https://www.ncbi.nlm.nih.gov/pubmed/35359969 http://dx.doi.org/10.3389/fimmu.2022.863039 |
Ejemplares similares
-
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
por: Barros-Martins, Joana, et al.
Publicado: (2021) -
Omicron infection-associated T- and B-cell immunity in antigen-naive and triple-COVID-19-vaccinated individuals
por: Barros-Martins, Joana, et al.
Publicado: (2023) -
BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
por: Behrens, Georg M. N., et al.
Publicado: (2022) -
Robust induction of neutralizing antibodies against the SARS‐CoV‐2 Delta variant after homologous Spikevax or heterologous Vaxzevria‐Spikevax vaccination
por: Hammerschmidt, Swantje I., et al.
Publicado: (2022) -
Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination
por: Hammerschmidt, Swantje I., et al.
Publicado: (2021)